In this video, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, shares some insights into a real-world study which evaluated treatment outcomes among patients with triple-class exposed (TCE) multiple myeloma, and further comments on the importance of conducting further studies like this to understand how the implementation of immunotherapies may play a role. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.